Fostering Collaboration to Advance Representative Enrollment in Clinical Trials
March 28, 2024
10:00 am - 2:45 pm ET
Virtual Public Convening

Meeting Objectives:
Building on the July 2023 Duke-Margolis public meeting, Advancing Representative Enrollment in Clinical Trials, this public convening seeks to highlight cross-cutting goals across interdisciplinary stakeholder groups to achieve representativeness in clinical trials. Topics will include building a sustainable foundation of community engagement; building and scaling innovative trial infrastructure; and funding and metrics needed to incentivize success.

Convening Agenda

10:00 am  Welcome
Trevan Locke, Duke-Margolis Institute for Health Policy

10:25 am  Session 1: Moving Beyond Targeted Outreach Towards Continual Community Engagement
Moderator: Sandra Yankah, Duke-Margolis Institute for Health Policy

Session Description: During this session, panelists will discuss collective efforts required to build a foundation of meaningful community engagement both during and after clinical trials. Panelists will address how community engagement extends beyond training and recruitment, emphasizing its wholistic and lasting impact on the community. The discussion will focus on scalable standards and the metrics needed to measure success.

Speakers and Panelists:
- Nadine Barrett, Wake Forest University School of Medicine
- Silas Buchanan, Institute for eHealth Equity
- Bridgette McCullough, ACIRAH Health
- Perla Nunes, Perla Nunes Consulting
- Andrea Thoumi, Duke-Margolis Institute for Health Policy

11:25 am  Break

11:35 am  Session 2: Building and Scaling Innovative Clinical Trial Infrastructure
Moderator: Trevan Locke, Duke-Margolis Institute for Health Policy
Session Description: During this session, panelists will discuss how leveraging innovative approaches to clinical trials can enhance representativeness and what supportive infrastructure might be required. Among other topics, panelists will address how point-of-care trials and other innovative trial approaches contribute to this effort, as well as barriers hindering progress in this area.

Speakers and Panelists:
- Meghan McKenzie, Genentech
- Martin Mendoza, National Institutes of Health
- Grail Sipes, Office of Science and Technology Policy
- Pamela Tenaerts, Medable, Inc.
- Amanda Wagner Gee, Milken Institute

12:35 pm Break
12:50 pm Session 3: Funding Considerations to Increase Representativeness in Clinical Trials
Moderator: Marianne Hamilton Lopez, Duke-Margolis Institute for Health Policy

Session Description: This session will explore actionable pathways funders can use to improve representativeness in clinical trials through the strategic use of funding and investments. Topics discussed will include funding mechanisms, incentive structures, and the development of compelling business cases for increasing representativeness. The discussion will also expand on topics covered in previous sessions to pinpoint avenues where funding can serve as a catalyst for change.

Speakers and Panelists:
- Jennifer Byrne, Javara
- Jennifer Gibson Levy, Henry Ford Health System
- Donna O’Brien, Manatt Health
- Priscilla Pemu, Morehouse School of Medicine

1:50 pm Session 4: Future Reflections
Moderator: Salimah El-Amin, Duke University

Session Description: In this closing session, panelists will reflect on the discussions throughout the day, considering how to turn collaborative priorities into action, as well as discuss potential metrics of success for such initiatives.

Speakers and Panelists:
- Barbara Bierer, Brigham and Women’s Hospital & Harvard Medical School
- Mimi Fenton, Walmart Healthcare Research Institute
- Adrienne Martinez-Hollingsworth, AltaMed Health Services
- Michel Reid, GSK
• Carolyn Shore, National Academies of Sciences, Engineering, and Medicine

2:35 pm  Concluding Remarks
Trevan Locke, Duke-Margolis Institute for Health Policy

2:45 pm  Adjournment

Support for this event was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.